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Two major categories of melanoma metastases have been
observed based on gene expression profiling and confir-
matory assays. One subgroup of patients has an inflamed
phenotype that includes expression of chemokines, T cell
markers, and other immunoregulatory factors. In contrast,
the other major subset lacks this phenotype and appears
to display immune “exclusion”. The optimal immunother-
apeutic intervention to gain clinical benefit may be distinct
in these two global subsets. The T cell-inflamed tumor
microenvironment subset contains the highest expression
of negative regulatory factors, including PD-L1, IDO, and
FoxP3+ Tregs, and clear evidence for T cell-intrinsic
anergy has also emerged. In addition, the mechanism of
induction of these inhibitory mechanisms has been eluci-
dated—PD-L1 and IDO are induced by IFN-g, and Tregs
are largely recruited by the chemokine CCL22, both being
produced by activated CD8+ effector T cells. Preclinical
experiments have confirmed a critical role for all 4 of
these mechanisms in limiting anti-tumor T cell efficacy in
vivo, giving candidate treatment strategies for translation
back into the clinic. These include anti-PD-1/PD-L1
mAbs, IDO inhibitors, and approaches to deplete CD25+
Tregs and/or reverse anergy. The presence of multiple
inhibitory mechanisms in the same tumor microenviron-
ment argues that combination therapies may be advanta-
geous to overcome compensatory effects. Preclinical
data indicated synergy between anti-CTLA-4 +/- anti-PD-
L1 +/- IDO inhibition. The mechanism of synergy is strik-
ing, as it correlates with a marked improvement of IL-2
production and proliferation of tumor-infiltrating CD8+
T cells. Clinical translation of these combination immu-
notherapies is promising and ongoing. In contrast to the
T cell-inflamed melanomas, a new paradigm may be
needed to promote de novo inflammation in cases of the
non-T cell-infiltrated tumor microenvironment. Natural
innate immune sensing of tumors appears to occur via the
host STING pathway, type I IFN production, and cross-
priming of T cells via CD8a+ DCs. New strategies are
being developed to engage or mimic this pathway as a
therapeutic endeavor.
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